Division of Medical Oncology, Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC), Princess Margaret Cancer Centre-University Health Network, Toronto, ON M5G 2C1, Canada.
Division of General Surgery, Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.
Curr Oncol. 2022 Jun 15;29(6):4260-4266. doi: 10.3390/curroncol29060340.
Sarcoma can present as locally advanced disease involving pleura for which extra-pleural pneumonectomy (EPP) may be the only surgical option to ensure adequate local control. Data were collected on patients who underwent EPP between January 2009 and August 2021 at Princess Margret Hospital and SickKids (Toronto) using the CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration). Ten patients with locally advanced sarcoma involving the pleura, aged 4 to 59 years (median 19.5 years) underwent EPP. Nine (90%) received pre-operative chemotherapy and eight (80%) achieved an R0 resection. Hemithoracic radiation was administered preoperatively ( = 6, 60%) or postoperatively ( = 4, 40%). Five (50%) patients were alive without disease at last follow-up (median 34.2 months) and time from EPP to last FU was median 29.2 months (range 2.2-87.5). Two patients (20%) had local recurrence, 4.3 and 5.8 months from EPP, and both died from progressive disease, 13.1 and 8.2 months from EPP, respectively. One patient died from brain metastasis (17 months), one died from radiation associated osteosarcoma (66 months), and one died from surgical complications (heart failure from constrictive pericarditis). EPP offers a feasible and life-prolonging surgical consideration for patients with locally advanced sarcoma involving the pleura in combination with chemotherapy and radiation. Consequently, EPP should be considered during multi-disciplinary tumor board discussions at high-volume centers.
肉瘤可表现为累及胸膜的局部晚期疾病,对于此类患者,施行胸膜外全肺切除术(EPP)可能是确保充分局部控制的唯一手术选择。本研究通过加拿大肉瘤研究和临床协作组(CanSaRCC),收集了 2009 年 1 月至 2021 年 8 月期间在玛格丽特公主医院和 SickKids(多伦多)行 EPP 的患者数据。10 例局部晚期累及胸膜的肉瘤患者,年龄 4 至 59 岁(中位数 19.5 岁),接受 EPP 治疗。9 例(90%)接受术前化疗,8 例(80%)达到 R0 切除。术前( = 6,60%)或术后( = 4,40%)行半胸放疗。5 例(50%)患者在最后一次随访时无疾病存活(中位数 34.2 个月),EPP 至末次 FU 的时间中位数为 29.2 个月(范围 2.2-87.5)。2 例(20%)患者出现局部复发,EPP 后分别为 4.3 和 5.8 个月,均死于疾病进展,EPP 后分别为 13.1 和 8.2 个月。1 例患者死于脑转移(17 个月),1 例死于放疗相关骨肉瘤(66 个月),1 例死于手术并发症(缩窄性心包炎引起的心力衰竭)。EPP 联合化疗和放疗为累及胸膜的局部晚期肉瘤患者提供了一种可行且延长生命的手术选择。因此,在高容量中心的多学科肿瘤委员会讨论中应考虑 EPP。